Decoding the genes behind dolastatin 10 paves the way for new cancer therapeutics

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

University of Florida College of Pharmacy researchers have pinpointed the genetic blueprints behind dolastatin 10, a marine natural product that has led to six FDA-approved cancer drugs since 2011. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

UF Health officials and supporters gathered Wednesday to unveil the UF Health Cancer Center’s Mobile Cancer Screening Connector, which will take cancer screening care to a 23-county area in North Florida. UF Health photo by Nate GuidryThe University of Florida Health Cancer Center launched a 40-foot-long mobile cancer screening bus that will expand access to cancer screenings and essential health care services, including 3D mammograms and cervical, colon, and prostate cancer screenings.
Kate Hitchcock, a UF Health radiation oncologist and an associate professor in the Department of Radiation Oncology in the UF College of Medicine, has been named associate director for access and opportunities at the UF Health Cancer Center. In this role, she will use her experience in leading clinical trials and broad range of healthcare experience to help the center train the next generation of cancer researchers, preparing them to lead advancements in the field.
Ivan Borrello, medical director of the Myeloma, Bone Marrow Transplant and Cell Therapies Program at Tampa General Hospital’s Cancer Institute, watched as flood waters from Hurricane Helene heaved against a contraption called the AquaFence, which is, as the name suggests, a water-impermeable barrier made of marine-grade laminate and various metals that can withstand storm surges of up to 15 feet above sea level. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login